Canada: Clinical Studies Exempted from Public Use in Allegation of Anticipation (Intellectual Property Weekly Abstracts Bulletin – Week Of June 2, 2014)

Last Updated: June 12 2014

Edited by Chantal Saunders and Beverley Moore , Adrian Howard and Ryan Steeves

NOC Cases

Clinical Studies Exempted from Public Use in Allegation of Anticipation

Bayer Inc. v. Apotex Inc., 2014 FC 436

Drug: YAZ® drospirenone and ethinylestradiol

This is an application pursuant to the Patented Medicines (Notice of Compliance) Regulations. The Court began by noting that it had issued an Order of prohibition in a proceeding relating to the same patent with a different generic company, Cobalt. The parties agreed not to make submissions with respect to obviousness in light of the Cobalt decision.

After construing the asserted claims, the Court found that Apotex did not infringe the patent. The Court also considered eligibility for listing on the Patent Register. The Court found that section 6(5) of the Regulationscan allow for the early disposition of this issue, but does not prevent the issue from being raised at the hearing. Accordingly, the Court considered Apotex' allegation that the patent was not properly listed on the Patent Register because the medicinal ingredient is in the form of a clathrate, which is not claimed in the patent. The Court noted the burden with respect to this allegation lies with Apotex because it is not an allegation that Bayer must demonstrate was not justified as it does with allegations pursuant to section 5(1) or (2) of the Regulations. The Court found that the listing was not improper.

Apotex also alleged that the asserted claims are invalid for anticipation in light of clinical studies in Europe and the United States. Bayer submitted evidence with respect to the measures taken to ensure confidentiality was maintained. The Court found "that there has been established a "theoretical" possibility that a tablet could have been kept and analyzed, therefore the requirements of subsection 28.2(1)(a) of the PatentAct have been met." However, the Court then considered that the law allows experimental use in order to bring an invention to perfection, which does not constitute public use. The Court found that Bayer took reasonable steps and it is only a theoretical possibility that some tablets were retained and analyzed. "This theoretical possibility does not preclude the fact that the studies were experimental, and of necessity, conducted by the provision of tablets to members of the public. Thus these clinical studies are exempted from public use." The claims of anticipation were found not justified.

The application was dismissed.

Patent Cases

Claim Seeking Punitive and Exemplary Damages Denied as Part of Section 8 Proceeding

TevaCanada Limited v. Pfizer Canada Inc., 2014 FCA 138

This is a case relating to the drug Viagra. This was an appeal from an order of the Federal Court which dismissed an appeal from an order of a Prothonotary. The Prothonotary had struck portions of Teva's Statement of Claim seeking punitive and exemplary damages, as well as quantification of Pfizer's profits, pursuant to an action under section 8 of the NOC Regulations.

The issue on this appeal was whether a claim for punitive and exemplary damages may be sustained under section 8 of the NOC Regulations. The Court of Appeal held that such a claim cannot be sustained, for similar reasons as those expressed by the Federal Court. The Court of Appeal added, however, that while punitive damages are not limited to certain categories of claims (i.e. they have been found to be available in all types of cases, notably in patent infringement cases), punitive and exemplary damages cannot be available where the statutory regime underlying the claim explicitly or implicitly precludes them. This is the case under the NOC Regulations, which set out a comprehensive scheme with respect to compensation resulting from the operation of the statutory stay it provides for. The Court of Appeal noted that section 8 of the NOC Regulations provides that the first person is liable for "any loss suffered" during the period; this wording allows compensation for losses actually incurred, not other types of relief, such as disgorgement of profits or punitive damages.

Teva also raised the application of subsection 8(5) of the NOC Regulations as a new justification for seeking punitive damages. The Court of Appeal clarified that this provision relates to the assessment of the losses suffered by the generic company, and that it allows the court to adjust the damages taking into account the conduct of the parties with respect to the prosecution of the prohibition application. However, it was held that subsection 8(5) cannot sustain a claim for punitive damages since, by their nature, punitive damages are not "compensation".

Teva's application was therefore dismissed.

Final injunction permits existing patients to continue to receive

infringing  medicine
AbbVie Corporation v. Janssen Inc., 2014 FC 489
Drug: ustekinumab (STELARA®)

This decision relates to the crafting of a final injunction for the sale of STELARA following a finding of infringement. In an earlier trial decision reported as 2014 FC 55, Janssen was found to be infringing AbbVie's Canadian Patent No. 2,365,281 by selling in Canada its product known as STELARA. (Currently under appeal, docket A-95-14) The Court of Appeal earlier refused to grant a stay of the hearing of arguments on this injunction pending the outcome of the appeal, due to a lack of finding of irreparable harm (2014 FCA 112, summarized here).

The Court refused to grant an injunction stopping all sales of STELARA, as existing patients may continue to receive the medicine. New patients may also be able to take the medicine, if the physician determines it is necessary to treat the patient. However, Janssen is barred from using sales representatives to promote the use of their product to doctors. Janssen was also prohibited from conducting Phase IV trials, unless they are required by law. The Court refused to stay the injunction pending the appeal.

Copyright Cases

Decision Granting Request for Case Management of IP Litigation Upheld on Appeal

The Grief Recovery Institute, LLC v. 1668246 Ontario Inc., 2012 FC 888

This was an appeal by the Defendants of the order of a Prothonotary granting the Plaintiffs' request for special management of this action, an action in which the Plaintiffs claim, among other things, copyright infringement and passing off. At the time of the hearing of this motion, the parties were at the close of the pleadings stage of the action.

The Plaintiffs filed a letter with the Federal Court requesting that the action be case managed for essentially two reasons: (1) to obtain a trial date at the earliest availability and avoid further delay; and
(2) to have in place a scheduling order, which will streamline all pre-trial matters. The Defendants did not consent on the ground that the request was premature. With respect to the Prothonotary's decision granting the Plaintiff's initial request, the Defendants submitted that it should be set aside because: (i) they did not consent; (ii) they were not permitted to be heard, which constituted a denial of natural justice; (iii) the request for case management was treated as an ex parte motion without any evidence filed; (iv) it was an error to grant the Plaintiff's order since the action is not complex litigation; and (v) the Prothonotary erred in law by automatically granting case management on request.

The Court could see no ground upon which it could find that the exercise of discretion by the Prothonotary was clearly wrong. What remained was the issue of whether the decision to issue the order was  based upon a wrong principle. The Court denied the Defendants' argument that it was denied natural justice, since no rights were being disposed of. While the Court conceded that the Prothonotary's decision is "open to criticism that he acted precipitously" and that he "could have waited" to issue the order, the Court did not accept the argument that the Prothonotary

was wrong in concluding that case management was appropriate in this case. It was a reasonable decision. While the Defendants argued that case management would be prejudicial to their interests (i.e. they would be foreclosed from bringing a motion for summary judgment, based on a reading of Rule 213(1) of the Federal Court Rules (the "Rules"), the draft Scheduling Order was crafted so as to limit the application and effect of Rule 213. In the Court's view, this was a complete answer to the Defendants' claim that they would suffer prejudice, since it is also consistent with the general principle in Rule 3 of the Rules. The Court also added that there is no requirement to show some form of delay by the parties prior to the issuance of such an order. In fact, it was noted that the relevant Practice Notice (May 2009) states that it should be made as early as possible. Therefore, the Defendants' appeal was dismissed.

The Plaintiffs sought and were awarded solicitor and client costs based on the fact that this appeal should not have been brought. The Court held that a less costly resolution could have been sought by a motion in writing to the Prothonotary to reconsider his Order.

Joint ownership in copyright ordered on basis of a memorandum assigning rights

Kennedy v. Ruminski, 2014 FC 526

The applicant moved under subsection 57(4) of the Copyright Act to correct the name of the holder of three copyright certificates, by naming the Applicant as the holder. The certificates are currently in the name of a programmer who either worked for or with the applicant. The main issue was whether the works were created during the course of employment, or whether they were partners.

The Court found that the applicant established an interest in the certificates. However, subsection 13(3) of the Copyright Act, which vests copyright in the employer, was found not to apply due to a memorandum between the two parties. The memorandum provides 80% ownership to the applicant, 20% to the respondent. In the result, the Court ordered that the registration certificates reflect joint ownership over the works.

Industry News

CIPO has released its Annual Report 2012-2013: A Year of Discovery.

About BLG

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions